Trials / Completed
CompletedNCT06494397
Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions
Crossover Bioequivalence Study of 12 mg VHX-896 and Iloperidone Tablets Under Steady-State Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Vanda Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Study to compare the pharmacokinetics and pharmacodynamics of VHX-896 and iloperidone and evaluate the safety and tolerability of VHX-896 and iloperidone in patients with schizophrenia or bipolar I disorder under steady state conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VHX-896 and iloperidone | oral tablet |
| DRUG | Iloperidone and VHX-896 | oral tablet |
Timeline
- Start date
- 2024-07-11
- Primary completion
- 2024-10-24
- Completion
- 2024-10-24
- First posted
- 2024-07-10
- Last updated
- 2025-09-19
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06494397. Inclusion in this directory is not an endorsement.